Apollo is leading a roughly €1.2 billion financing package to support the buyout of Karo Healthcare by KKR, according to market sources.
Apollo is joined by lenders including Goldman Sachs Asset Management, CVC, JP Morgan, KKR Credit and others, sources said. The financing package includes a €1.125 billion term loan, with the remainder as a delayed-draw facility, sources said. The term loan is priced at around E+475 bps, sources added. As many as 10 lenders are said to be providing the financing.
Win for direct lenders
The deal represents a win for direct lenders, as banks had also pitched to provide financing to support the acquisition — but it appears broader market volatility has tipped the balance in favour of direct lenders for this deal, sources said.
KKR, Apollo, CVC, and JPMorgan declined to comment. Emailed queries sent to GSAM remained unanswered.
KKR earlier this month said it had agreed to buy Karo Healthcare from EQT in a deal valuing the business at roughly €2.5 billion. In January 2019, EQT (through Karo Intressenter AB) acquired a majority stake in Karo Healthcare, formerly known as Karo Pharma.
Headquartered in Sweden, Karo specializes in the sale and marketing of prescription pharmaceuticals and over-the-counter products sold in pharmacies and other retail outlets. The firm employs roughly 450 people working out of 12 international hubs, according to its website.
fotograzia/Getty Images
Learn about our editorial standards.